HABERMAN ASSOCIATES NEWS PAGE
2008 News
May 9, 2008: Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Blood-Brain Barrier: Bridging Options for Drug Discovery and Development, by Allan B. Haberman, Ph.D. This new Insight Pharma Report reviews novel technologies designed to enable small and large molecule drugs to efficiently cross the blood-brain barrier. The inability of most drugs to cross the blood-brain barrier is a major bottleneck in the development of central nervous system (CNS) drugs, especially novel drugs aimed at major unmet needs in the CNS area, such as Alzheimer's disease, Parkinson's disease, ALS, and stroke.

The report will be of special interest to you if you are involved in the research, development, licensing, or portfolio management of current and potential CNS therapeutics. It will also be of interest to you if you are interested in assessing new opportunities in CNS diseases for your company.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
 

January 1, 2008: Genetic Engineering News published an article by Allan B. Haberman, Ph.D. in its January 1, 2008 edition, entitled "Addressing Unmet Type 2 Diabetes Needs". This article is based in part on our recent book-length report, Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D, published by Cambridge Healthtech Institute (CHI).
 

2007 News
  September 6, 2007: Allan B. Haberman, Ph.D., was quoted in two articles on the metabolic disease drugs lorcaserin (Arena Pharmaceuticals) and exenatide (Amylin/Lilly's Byetta) on the Pharmawire news service. The articles were published on September 4 and September 6, respectively.

Pharmawire is an online subscription-based news service that focuses on news and data on the global pharmaceutical market. It is owned by the Financial Times Group, the publisher of the Financial Times.
 

April 27, 2007: Cambridge Healthtech Institute (CHI) announced the publication of a new book-length report, Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D, by Allan B. Haberman, Ph.D. This new Insight Pharma Report (formerly Advances Reports), provides a strategic perspective on the field of drugs for diabetes and its complications, with an emphasis on novel and emerging drugs and therapeutic strategies.

The report will be of special interest to you if you are involved in the research, development, licensing, or portfolio management of current and potential diabetes therapies. It will also be of interest to you if you work in other metabolic disease areas (e.g., obesity and cardiovascular disease), or if you are interested in assessing new opportunities in metabolic diseases for your company.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
 

March 7, 2007: Allan B. Haberman, Ph.D. was quoted in an article entitled "FDA and Acomplia: Stuck on Each Other?" by Beth Herskovits, in the March 7 issue of Pharmaceutical Executive's weekly newsletter PharmExec Direct.  The article was about antiobesity drugs, with the focus on Sanofi-Aventis' Acomplia (rimonabant).

The article is available at http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=409028